Invalid Symbol

Stock Research for BIOVF

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


BIOVF Stock Chart & Research Data

The BIOVF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOVF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BIOVF Due diligence Resources & Stock Charts

The BIOVF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOVF Detailed Price Forecast - CNN Money CNN View BIOVF Detailed Summary - Google Finance
Yahoo View BIOVF Detailed Summary - Yahoo! Finance Zacks View BIOVF Stock Research & Analysis -

Stock Analysis

TradeIdeas View BIOVF Trends & Analysis - Trade-Ideas Barrons View BIOVF Major Holders - Barrons
NASDAQ View BIOVF Call Transcripts - NASDAQ Seeking View BIOVF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOVF Annual Report - OTC Report View BIOVF OTC Short Report -
TradeKing View BIOVF Fundamentals - TradeKing Charts View BIOVF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOVF - The WSJ Morningstar View Performance/Total Return for BIOVF - Morningstar
MarketWatch View the Analyst Estimates for BIOVF - MarketWatch CNBC View the Earnings History for BIOVF - CNBC
StockMarketWatch View the BIOVF Earnings - StockMarketWatch MacroAxis View BIOVF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOVF Bullish Patterns - American Bulls Short Pains View BIOVF Short Pain Metrics -

Social Media Mentions

StockTwits View BIOVF Stock Mentions - StockTwits PennyStocks View BIOVF Stock Mentions - PennyStockTweets
Twitter View BIOVF Stock Mentions - Twitter Invest Hub View BIOVF Investment Forum News - Investor Hub
Yahoo View BIOVF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOVF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOVF - Insider Cow View Insider Transactions for BIOVF - Insider Cow
CNBC View BIOVF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOVF - OTC Markets
Yahoo View Insider Transactions for BIOVF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOVF - NASDAQ

Stock Charts

FinViz View BIOVF Stock Insight & Charts - StockCharts View BIOVF Investment Charts -
BarChart View BIOVF Stock Overview & Charts - BarChart Trading View View BIOVF User Generated Charts - Trading View

Latest Financial News for BIOVF

Invitation - Presentation of Sobi's Q4/FY 2017 Results
Posted on Tuesday February 13, 2018

STOCKHOLM , Feb. 13, 2018 /PRNewswire/ -- On 22 February, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2017. Financial analysts ...

The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta®
Posted on Thursday October 26, 2017

STOCKHOLM, Oct. 27, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) announces today that the first patient has been enrolled in the open-label, multicentre ReITIrate study (NCT03103542). The ReITIrate study is designed to investigate the immune tolerance induction (ITI) potential of Elocta® (efmoroctocog alfa) in patients with haemophilia A who have developed inhibitors which have failed to be resolved with other therapies. The development of antibodies (inhibitors) that neutralise the effect of factor VIII is one of the most serious complications to haemophilia A treatment, making standard replacement therapy ineffective, increasing the risk for severe bleeding and morbidity, decreasing quality of life and increasing health care costs[i].

Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Posted on Tuesday October 24, 2017

STOCKHOLM , Oct. 25, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix® (eftrenonacog ...

Norbert Oppitz Joins Sobi™ as New Senior Vice President, Specialty Care
Posted on Thursday October 05, 2017

STOCKHOLM , Oct. 6, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established business area ...

Taking Aim at Swedish Orphan Bio S/Adr (SWTUY) Technical Levels
Danvers Record - Feb 20, 2018
Swedish Orphan Bio S/Adr (SWTUY) shares are being closely watched as the Rank Correlation Indicator has shown an upward 3 bar near-term trend, indicating that a reversal might be near.

Surface Oncology Expands Board of Directors
Business Wire (press release) - 16 hours ago
Dr. McDonough is president and CEO of Generation Bio which he helped launch earlier this year. Dr. McDonough previously served as president and CEO of Swedish Orphan Biovitrum AB (Sobi) from 2011 until 2017, where he led the expansion of the company's ...

The Swedish Orphan Bio Spon (SWTUY) Lifted to Buy at Zacks Investment Research
BangaloreWeekly - Feb 18, 2018
Zacks Investment Research upgraded shares of Swedish Orphan Bio Spon (NASDAQ:SWTUY) from a hold rating to a buy rating in a report issued on Saturday morning.

Atlas Venture Launches Generation Bio
Business Wire (press release) - Jan 4, 2018
Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology, which delivers high levels of durable gene expression and can be re-dosed to titrate and sustain effect.

Enter a stock symbol to view the stock details.